Science & Technology
Science and Technology
Science and Technology
Wed, January 28, 2009
IRIS Ranked Number One in MD Buyline Review of Leading Industry Automated Urinalysis Competitors
CHATSWORTH, Calif.--([ BUSINESS WIRE ])--IRIS INTERNATIONAL, INC. (NASDAQ: IRIS), a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide,today announced that its IRIS Diagnostics Business Unit has earned the highest vendor satisfaction ratings from among a group of four leading vendors of automated urinalysis systems.
The ratings, which were published in MD Buyline's Q4-2008 Market Outlook - User Satisfaction Ratings Survey on January 1, 2009, place IRIS Diagnostics as number one among industry competitors, with a composite ranking of 8.6 out of 10. The other vendors in the group were Roche, Siemens and Sysmex. IRIS achieved the highest ratings in four out of six categories, including System Performance, System Reliability, Installation/Implementation, and Applications Training, and the second highest ratings in the remaining two categories of Service Response Time and Service Repair Quality.
MD Buyline, a leading independent healthcare research and market intelligence organization, provides independent analysis and reporting. It measures user satisfaction by surveying each vendor's installed base, with hospitals and clinical reference laboratories ranking their satisfaction in six categories.
"We are honored to achieve these ratings in the MD Buyline survey. MD Buyline is a leading authority on healthcare market intelligence to more than 3300 hundred facilities and 35,000 members. Achieving the top ratings among MD Buyline's most recent survey is a testament to IRIS's continuing emphasis and commitment to improving upon and maintaining the highest level of quality control and customer satisfaction for our iQ®200 Automated Urinalysis System," stated Thomas Warekois, Corporate Vice President and President of the IRIS Diagnostics Business Unit. "These latest rankings are evidence of the continued hard work and dedication of the entire IRIS team, which have made this achievement possible," he added.
About MD Buyline
MD Buyline, founded in 1983, and based in Dallas, is an industry-leading provider of research, information and consultation to help healthcare providers make sound decisions when buying and implementing capital expenditures and information technologies. The company provides objective information that helps healthcare providers reduce risk, contain costs, and increase efficiencies by offering reliable data, strategic analysis, and counsel. Its data assists healthcare providers through every phase of the purchasing process from researching emerging technologies to final negotiations. For more information, visit [ www.mdbuyline.com ].
About IRIS International
IRIS International is a leading global in vitro diagnostics company focused on products that analyze particles and living cell forms and structures, or morphology of a variety of body fluids. The Company's products leverage its strengths in flow imaging technology, particle recognition and automation to bring efficiency to hospital and commercial laboratories. The initial applications for its technology have been in the urinalysis market and the Company is the leading worldwide provider of urine microscopy systems, with more than 2,100 systems sold in over 50 countries. For more information, visit [ www.proiris.com ].
SAFE HARBOR PROVISION
This press release contains forward-looking statements made in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, the Company's views on future financial performance, market growth, capital requirements, regulatory developments, new product introductions and acquisitions, and are generally identified by phrases such as "thinks," "anticipates," "believes," "estimates," "expects," "intends," ,"plans," and similar words. Forward-looking statements are not guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statement. These statements are based upon, among other things, assumptions made by, and information currently available to, management, including management's own knowledge and assessment of the Company's industry, R&D initiatives, competition and capital requirements. These and other risks are more fully described in the Company's filings with the Securities and Exchange Commission, including the Company's most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q, which should be read in conjunction herewith for a further discussion of important factors that could cause actual results to differ materially from those in the forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
